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Abstract
Introduction: The normalization of cellular glucose assimilation is the basic aim of therapy in diabetes mellitus. This process should be
accompanied by a proportional increase of the cellular glucose transport (CGT). The level of CGT should react to therapy typically recom-
mended in Type 2 diabetes mellitus (T2DM), composed of diet and sulfonylurea. In order to explore this clinically significant hypothesis,
a clinical-experimental study was undertaken. Its aim was to determine the clinical pharmacotherapeutic significance of CGT measure-
ments.
Material and methods: CGT testing was performed on peripheral blood lymphocytes. CGT was assessed with 2-[3H(G)] glucose: before,
and after the addition of sulfonylurea or sulfonylurea plus insulin to the incubation medium. Tests were performed at baseline in
28 persons with newly diagnosed, “therapeutically naive” T2DM and in 20 control subjects. In diabetic patients the tests for CGT were
repeated after 3 months of routine diet and sulfonylurea therapy. In addition, the level of GLUT4 expression was assessed by flow cytome-
try before and after this therapy.
Results: Before treatment, CGT was significantly decreased in all subjects with T2DM. Incubated in-vitro cells responded directly to the
addition of sulfonylurea with a moderate increase of CGT. This response was augmented by the addition of insulin to sulfonylurea in the
incubation medium. The monitored three-month routine, controlled therapy with diet and sulfonylurea resulted in a significant increase
of CGT process in all types of incubation tests.
Conclusions: The basal and reactive CGT is significantly decreased in lymphocytes of persons with T2DM before the introduction of
therapy. Effective therapy with diet and sulfonylurea normalizes both types of CGT — basal and reactive. It is related to the near norma-
lization of GLUT4 expression in the studied cells. This phenomenon may be used as a new marker for diabetes mellitus pharmacotherapy.
(Pol J Endocrinol 2010; 61 (1): 75–81)
Key words: sulfonylurea, cellular glucose transport, lymphocyte model for cellular glucose transport, GLUT4 expression, pharmacotherapeutic
markers
Streszczenie
Wstęp: Podstawowym celem w leczeniu cukrzycy jest normalizacja komórkowej asymilacji glukozy. Temu procesowi musi towarzyszyć
proporcjonalne zwiększenie dokomórkowego transportu glukozy (CGT, cellular glucose transport). Wielkość CGT powinna zmieniać się
w odpowiedzi na leczenie cukrzycy typu 2, które obejmuje dietę i stosowanie pochodnych sulfonylomocznika. Aby zbadać tę istotną
z klinicznego punktu widzenia hipotezę, przeprowadzono badanie kliniczno-doświadczalne. Miało ono na celu określenie znaczenia
pomiarów CGT w ocenie skuteczności farmakoterapii.
Materiał i metody: Dokomórkowy transport glukozy oceniono na podstawie poboru glukozy 2-[3H(G)] przez limfocyty krwi obwodowej
badanych osób przed i po dodaniu do medium pochodnej sulfonylomocznika lub pochodnej sulfonylomocznika i insuliny. Pomiar prze-
prowadzono wyjściowo u 28 chorych z nowo rozpoznaną cukrzycą typu 2, niestosujących wcześniej żadnego leczenia, i u 20 zdrowych
ochotników stanowiących grupę kontrolną. W grupie chorych na cukrzycę pomiar CGT powtórzono po 3 miesiącach stosowania diety
i pochodnych sulfonylomocznika. Ponadto przed rozpoczęciem terapii i po jej zastosowaniu oceniono poziom ekspresji GLUT4 za po-
mocą cytometrii przepływowej.
Wyniki: Przed leczeniem u wszystkich chorych na cukrzycę typu 2 CGT był istotnie zmniejszony. W komórkach inkubowanych in vitro
bezpośrednią odpowiedzią na dodanie do medium pochodnej sulfonylomocznika był umiarkowany wzrost CGT. Odpowiedź ta była
silniejsza, kiedy do inkubowanych komórek poza pochodną sulfonylomocznika dodano również insulinę. Po 3 miesiącach kontrolowane-
go leczenia dietą i pochodną sulfonylomocznika stwierdzono istotne zwiększenie CGT we wszystkich inkubowanych próbkach.
Wnioski: Przed zastosowaniem terapii podstawowy i reaktywny CGT w limfocytach osób chorych na cukrzycę typu 2 był istotnie obniżo-
ny. Skuteczne leczenie dietą i pochodną sulfonylomocznika spowodowało normalizację CGT — zarówno podstawowego, jak i reaktyw-
nego. Powyższe korzystne zmiany były następstwem znacznej poprawy ekspresji GLUT4 w badanych komórkach. To zjawisko może
zostać wykorzystane jako nowy wskaźnik w ocenie farmakoterapii cukrzycy typu 2. (Endokrynol Pol 2010; 61 (1): 75–81)
Słowa kluczowe: pochodna sulfonylomocznika, dokomórkowy transport glukozy, limfocytarny model dokomórkowego transportu glukozy,
ekspresja GLUT4, wskaźniki farmakoterapeutyczne
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Introduction
The bilayer lipid membrane of the majority of cells in
the human body is impermeable to monosacharides,
and, therefore, glucose needs a biological transport sys-
tem consisting of specialized transport proteins — glu-
cotransporters [1, 2]. These proteins provide the phy-
siological balance between the glucose cell supply and
its further metabolism [3, 4].
Cellular glucose transport (CGT) is a complex mul-
tistage process. Individual stages of the process are co-
ordinated by specialized regulatory systems. In physio-
logical conditions, the sensitive quantitative coordina-
tion between the activity of the molecular CGT system
and the glucose intracellular metabolism is related to
glycaemia. Insulin is among the most important regu-
lators of this relationship [5].
In diabetes mellitus, however, this physiological re-
gulation becomes impaired. Glucose utilization by the
cells is diminished despite the existence of hyperglyca-
emia. This is mostly because of disturbances of insulin
regulatory action on CGT due to its deficiency or to in-
sulin resistance. This pathogenetic phenomenon con-
cerns CGT efficiency. Determination of the CGT pro-
cess may point to a new specific pathophysiological
background of hyperglycaemia which could be impor-
tant for more precise differentiation of type 2 diabetes
mellitus subtypes. It may also serve as an index of the-
rapeutic efficiency.
In order to answer these pathophysiologically and
clinically important questions, special research experi-
ments were designed and performed. The investigations
included:
— the comparative assessment of CGT in healthy vo-
lunteers and in newly diagnosed type 2 diabetes
mellitus patients who had not previously been tre-
ated in any way;
— the assessment of the influence of type 2 diabetes
mellitus treatment with diet and sulfonylurea com-
pound on CGT;
— the study of changes of GLUT4 expression — the glu-
cotransporter playing the most important role in CGT
— which could take place as an effect of type 2 diabetes
mellitus routine treatment with diet and sulfonylureas.
Peripheral blood lymphocytes of patients with type 2
diabetes mellitus and of healthy subjects were used as
the cell model for the CGT in vitro testing.
Material and methods
Clinical characteristics of examined patients
Type 2 diabetes mellitus group
A group of 28 patients with type 2 diabetes mellitus who
were not previously treated pharmacologically was
qualified for the study. Clinical diagnosis of type 2 dia-
betes was made according to World Health Organiza-
tion criteria. The qualification of the study population
was accepted by the University Bioethics Council. The
chosen subjects had no pathological disorders other
than type 2 diabetes mellitus.
Control group
The control group was made up of 20 healthy volunte-
ers with no family history of diabetes mellitus Qualifi-
cation was based on a complete clinical examination in
accordance with the full protocol of Warsaw Medical
University clinical standards.
In patients with type 2 diabetes, the eight-point da-
ily glycemia profile and HbA1c measurements were
performed. In the control group, an oral glucose tole-
rance test (75.0 g) was performed according to WHO
standards.
Results of the initial clinical examination of both gro-
ups are presented in Table I.
Plan of the CGT process and GLUT4 expression
testing experiments
CGT assessment in peripheral blood lymphocytes
in vitro:
— The lymphocyte suspension samples were tested in
accordance with the study plan, as taken from:
• 20 healthy control subjects,
• 28 type 2 diabetes mellitus patients with no pre-
vious treatment of hyperglycaemia, before and
after a period of three-month controlled therapy
with diet and sulfonylurea.
— The influence of sulfonylurea treatment on the CGT
was studied in three independent series of lympho-
cyte incubation tests:
• with neither sulfonylurea nor insulin added,
• with sulfonylurea „in substantia” added,
• with both sulfonylurea „in substantia” and insulin
added.
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The CGT level was measured at the 15th, 30th, and
60th minutes of incubation.
In all cases and samples, the viability of lymphocy-
tes was tested with the trypan blue method.
GLUT4 expression:
GLUT4 expression was measured in the lymphocytes
of the same subjects who had CGT determined:
— in 10 healthy control subjects;
— in 10 type 2 diabetes mellitus patients;
— before and after sulfonylurea therapy.
Laboratory methods
Measurement of deoxy-D-glucose uptake
by lymphocytes
The incubation tests were performed according to pre-
viously described methodology [6–8], adapted to our
research laboratory.
To the 290 µl of suspension containing 300 000 lym-
phocytes, 1.5 µl of deoxy-D-glucose, 2-[3H(G)] – 185–
–370 GBq (5–10 Ci) mmol (NEN Life Science Products,
Inc.) and 7.5 µl of PBS solution (Phosphate Buffer Sali-
ne) was added. Deoxy-D-glucose, 2-[3H(G)] uptake was
measured after 15, 30, and 60 minutes of incubation:
Glucotransporter 4 expression measurements
with the use of flow cytometry
Mononuclear cells were isolated from blood samples on
Gradisol L (fluid density of 1.077 g/L, „AQUA-MEDICA”)
and washed twice in 0.9% NaCl.
To mark the population of cells that presented GLUT
4 protein expression, monoclonal antibody (MoAb) anti-
GLUT4 was used together with single colour, indirect
immunofluorescence technique.
For data acquisition and analysis, a FascCalibur flow
cytometer (BectonDickinson, USA) with CellQuest so-
ftware (Becton-Dickinson) was used. The results were
given as the percentage of cells presenting the expres-
sion of the investigated protein (9).
Viability test
Testing lymphocytes with trypan blue showed that the
experimental methods used had not influenced lym-
phocyte viability.
Statistical analysis
Comparison of clinical, demographic, CGT, and GLUT4
expression parameters in the examined groups was
performed using the Student, Mann Whitney, or Chi-
square tests, as appropriate. Variations in glucose upta-
Table I. Comparative clinical characteristics of the 2 study groups — diabetes mellitus type 2 and control group
Tabela I. Porównawcza charakterystyka kliniczna 2 badanych grup — chorych na cukrzycę typu 2 i grupy kontrolnej
Parameter Diabetes mellitus type 2 Control group P
group (before the treatment) n = 20
n = 28
Mean SD Mean SD
Age (years) 58.0 7.0 48.6 11.4 0.003
Sex M/F 20/8 8/12
BMI [kg/m2] 28.49 2.21 27.68 2.44 0.235
Blood pressure [mm Hg]:
— systolic 135.4 14.8 127.3 13.3 0.060
— diastolic 79.3 8.0 77.0 9.2 0.365
Resting heart rate [min] 80.0 7.4 80.4 8.7 0.865
FPG [mmol/L] 8.05 1.03 5.13 0.66 < 0.001
FSI [mU/ml] 12.15 7.88 7.92 3.76 0.019
HOMA-IR 4.368 2.806 1.844 1.008 < 0.001
HbA1c (%) 6.83 0.86 –
Creatinine, serum [mg/ml] 1.020 0.310 0.944 0.177 0.291
AspAT [IU/dL] 25.5 8.1 20.6 5.9 0.024
AlAT, [IU/dL] 26.9 13.6 24.0 10.4 0.426
FPG — fasting plasma glucose; FSI — fasting serum insulin; HOMA-IR — homeostatic model assessment — insulin resistance; AspAT — aspartate
transaminase, serum; AlAT — alanine transaminase, serum
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ke in peripheral blood lymphocytes were analyzed with
Student’s test [10].
Results
CGT assessment in peripheral blood lymphocytes
— control group and diabetes mellitus group
before therapy with diet and sulfonylurea
1. CGT incubation tests with lymphocytes of control
subjects. The tests showed the existence of active
CGT. Its effects clearly increased with the duration
of incubation. The addition of sulfonylurea to the
incubation environment enhanced the CGT by a sta-
tistically significant degree for all investigated incu-
bation periods. The addition of sulfonylurea and
insulin together intensified the CGT at periods of
15 and 30 minutes. This phenomenon did not appe-
ar at the incubation period of 60 minutes (Table II).
2. Incubation tests in type 2 diabetes patients.
When sulfonylurea „in substantia” was not added
to the incubation environment, the CGT values were
lower than were those in healthy control subjects. The
influence of sulfonylurea and sulfonylurea together
with insulin added to the incubation environment was
distinctly weaker in samples from diabetic patients not
treated pharmacologically, in comparison with healthy
control subjects (Table III).
Assessment of the CTG in peripheral blood
lymphocytes after prolonged therapy
with diet and sulfonylurea
Diabetes mellitus metabolic compensation parameters,
as compared to those measured before the start of typi-
cal treatment and after 12 weeks of treatment with diet
and sulfonylurea, improved significantly.
Fasting plasma glucose concentration significantly
decreased (on average by 1.77 mmol/L, P < 0.001). This
was associated with a decrease of the HbAlc level (on
average by 0.69%, P < 0.001). Fasting plasma insulin
concentration increased at the same time, on average,
by 2.65 mU/ml (P < 0.022). The HOMA-IR index did not
change.
In type 2 diabetes mellitus treated typically for
12 weeks with diet and sulfonylurea, the CGT intensity
was significantly and consistently higher than before
therapy. The significant therapeutic reactivity of the
CGT was clearly observed (Table IV).
GLUT4 expression measurement
The results of GLUT4 expression measurement in pe-
ripheral blood lymphocytes for control subjects and
for type 2 diabetic patients under study, measured
before the start of the diet and sulfonylurea treatment
and after 12 weeks of such routine therapy, are pre-
sented in Table V.
Table II. CGT efficiency measured in incubation tests, in vitro, for peripheral blood lymphocytes taken from 20 control subjects
expressed in pg/300 000 lymphocytes
Tabela II. Skuteczność CGT mierzona w testach inkubacyjnych, in vitro, w limfocytach krwi obwodowej pobranych
od 20 zdrowych osób z grupy kontrolnej wyrażona w pg/300 000 limfocytów
Sample Model Incubation time [min] CGT intensity [pg/300 000 lymphocytes]
Min Max Median Mean SD
1 Lymphocytes, no drugs added 15’ 62.4 156.0 128.5 123.1 25.7
30’ 88.0 305.6 237.2 228.7 58.8
60’ 127.9 593.4 479.5 442.8 137.8
2 Lymphocytes, gliclazide in substantia added 15’ 94.5 268.0 219.8 203.6 49.1
30’ 212.6 547.4 451.0 417.1 107.1
60’ 289.2 860.3 726.3 664.1 186.8
3 Lymphocytes, gliclazide in substantia 15’ 118.1 399.4 346.8 308.8 87.2
and insulin added
30’ 285.5 855.5 704.2 647.7 181.5
60’ 292.7 876.8 721.7 666.7 186.4
sample 2 v. 1 15’ < 0.001
30’ < 0.001
p 60’ < 0.001
sample 3 v. 2 15’ < 0.001
30’ < 0.001
60’     0.469
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Table III. CGT intensity measured in incubation tests, in vitro, for peripheral blood lymphocytes taken from 28 type 2
diabetes patients, at baseline, expressed in pg/300 000 lymphocytes
Tabela III. Intensywność CGT mierzona w testach inkubacyjnych, in vitro, w limfocytach krwi obwodowej pobranych od
28 chorych na cukrzycę typu 2, wyjściowo wyrażone w pg/300 000 limfocytów
Sample Model Incubation time [min] CGT intensity [pg/300 000 lymphocytes]
Min Max Median Mean SD
1 Lymphocytes, no drugs added 15’ 20.4 147.9 108.7 106.4 25.3
30’ 62.3 225.6 188.4 179.4 32.3
60’ 79.2 355.3 265.2 263.1 47.8
2 Lymphocytes, gliclazide in substantia added 15’ 20.5 179.6 116.1 113.5 25.8
30’ 41.4 248.8 205.4 199.0 36.3
60’ 89.4 380.3 332.6 316.2 57.8
3 Lymphocytes, gliclazide in substantia 15’ 66.9 231.3 187.4 186.4 28.4
and insulin added
30’ 79.5 373.1 311.9 293.3 56.7
60’ 84.5 384.3 323.7 306.0 57.1
sample 2 v. 1 15’     0.118
30’ < 0.001
p 60’ < 0.001
sample 3 v. 2 15’ < 0.001
30’ < 0.001
60’ < 0.001
Table IV. CGT intensity measured in incubation tests, in vitro, for peripheral blood lymphocytes taken from 28 diabetes type 2
patients, after the completion of 12 weeks gliclazide treatment expressed in pg/300 000 lymphocytes
Tabela IV. Intensywność CGT mierzona w testach inkubacyjnych, in vitro, w limfocytach krwi obwodowej pobranych od
28 chorych na cukrzycę typu 2 po zakończeniu 12-tygodniowego leczenia gliklazydem i wyrażona w pg/300 000 limfocytów
Sample Model Incubation time [min] CGT intensity [pg/300 000 lymphocytes]
Min Max Median Mean SD
1 Lymphocytes, no drugs added 15’ 72.4 212.9 153.0 162.4 34.6
30’ 141.2 397.2 293.2 308.1 57.5
60’ 289.9 611.5 567.0 543.6 62.1
2 Lymphocytes, gliclazide in substantia added 15’ 77.7 261.3 224.2 210.3 36.7
30’ 151.2 569.0 405.4 412.0 97.3
60’ 298.5 957.0 663.4 727.2 147.5
3 Lymphocytes, gliclazide in substantia 15’ 144.3 405.5 360.4 349.3 54.5
and insulin added
30’ 295.0 891.0 617.4 689.6 145.2
60’ 296.5 932.7 644.1 709.7 150.0
sample 2 v. 1 15’ < 0.001
30’ < 0.001
p 60’ < 0.001
sample 3 v. 2 15’ < 0.001
30’ < 0.001
60’ < 0.001
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In control subjects, GLUT4 expression was observed
in 0.6% of lymphocytes. In type 2 diabetes mellitus pa-
tients before treatment, this value was much higher
— 15.5% of lymphocytes presented GLUT4 expression.
Under the influence of treatment with diet and sulfo-
nylurea, the level of GLUT4 expression was diminished
to a mean value of 2.7%.
Discussion
Clinical research of CGT concerns only selected areas.
It has already provided valuable information regarding
the activity and regulation of CGT and glucotranspor-
ter expression in humans under various conditions,
both physiological and pathological [8, 9, 11–13]. In
the majority of such studies, myocytes or adipocytes
were used as the experimental model. At the same
time, other cell models were practically ignored. The
therapeutic significance of CGT abnormalities were
rarely undertaken.
There are examples of CGT pharmacological rese-
arch made on animal models, which could be analyzed
in connection with the presented study. Tsiani E. et al.
investigated the influence of sulfonylurea on the CGT
intensity and on glucose transporter distribution in rat
muscle tissue cells in vitro. They demonstrated that sul-
fonylurea causes a significant increase in CGT, indepen-
dently from insulin. This phenomenon correlated with
the increase in GLUT1 expression in the plasma mem-
brane of the tested cells [12].
Interesting information concerning sulfonylurea
influence on CGT in rat muscles was also presented by
Pulido et al. [13, 14]. Sulfonylurea increased the CGT and
enhanced GLUT4 translocation to the cell membrane.
This direct effect was stimulated by insulin. Sulfonylu-
rea compound administered to rats with streptozocine
induced diabetes mellitus, normalizing both GLUT4
expression and the CGT in skeletal muscle tissue [13].
Table V. The percentage of peripheral blood lymphocytes presenting GLUT4 expression for control group and for type 2 diabetic
patients before and after 12 weeks of gliclazide treatment
Tabela V. Odsetek limfocytów krwi obwodowej, w których stwierdzono ekspresję GLUT4 w grupie kontrolnej i u chorych na
cukrzycę typu 2 przed i po 12 tygodniach stosowania gliklazydu
Percentage of lymphocytes with GLUT4 expression
Control subjects Type 2 diabetes mellitus patients
Mean SD Before  gliclazide After 12 weeks of
treatment (W0) gliclazide treatment (W12)
Mean SD Mean SD
0.6 0.3 15.5 9.8 2.7 1.6
p (W0 v. W12) = 0.002; SD — standard deviation
The results of the CGT study indicate abnormalities
in CGT function in type 2 diabetic patients. Experiments
revealed that typical therapy with diet and sulfonylu-
rea significantly affects the CGT.
Comparison of the CGT measured in incubation te-
sts at time periods of 15, 30, and 60 minutes in healthy
subjects and in type 2 diabetic patients both untreated
and subjected to 12 weeks of typical diet and sulfony-
lurea treatment provides important information on this
issue. It was found that in untreated type 2 diabetic
patients, the CGT in all in vitro testing measurements
was significantly diminished compared with the valu-
es for control subjects. In untreated type 2 diabetes
mellitus, two phenomena coexisted: hyperglycaemia
and significant decrease of CGT. After 12 weeks of ro-
utine controlled diet and sulfonylurea therapy, the pre-
viously decreased CGT increased to a level similar to
that observed in control subjects. This phenomenon
correlated with a significant decrease of glycaemia and
the HbAlc percentage. It could be regarded, therefore,
as a measure and an aim of the therapy.
This opinion is supported by the observation of
GLUT4 expression by peripheral blood lymphocytes in
relation to the therapy of diabetes mellitus. Several stu-
dies so far have revealed that GLUT1, GLUT3, GLUT4,
and GLUT9 are present in granulocytes and monocy-
tes [15–17]. In lymphocytes, the expression of GLUT1,
GLUT3, and GLUT9 has been shown [9, 15, 16]. Surpri-
singly, in the study results available to date, no GLUT4
expression in lymphocytes from healthy people has
been observed [17, 18]. The expression of the GLUT1
gene in lymphocytes from rat spleen increases under
the influence of physical exercise [19, 20]. On the other
hand, it has been shown that sustained hypoglycaemia
affects GLUT genes expression in human blood leuko-
cytes, especially in granulocytes and monocytes. In gra-
nulocytes the level of GLUT4 increases in this situation
by 73%, as compared with control samples, whereas
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a simultaneous reduction of GLUT1 and GLUT3 is ob-
served. No such effect has been observed in the lym-
phocyte population [18].
In type 2 diabetes mellitus patients, two effects were
noted simultaneously: an increase in the CGT and
a decrease in GLUT4 expression - both close to the va-
lues observed in healthy people. The respective decre-
ase of GLUT4 expression was from the mean value of
15.5% to the mean value of 2.7% cells (P < 0.001) as
measured with flow cytometry technique. This is also
a definitely positive therapeutic effect. Our observations
suggest that therapy directly affected the CGT system.
Conclusions
To summarize, routine therapy with diet and sulfony-
lurea in type 2 diabetes mellitus simultaneously exer-
ted a positive influence on both CGT efficiency and
GLUT4 expression.
In conclusion, it could be stated, that:
1. The incubation tests show that lymphocytes consti-
tute a useful model for CGT investigations. In heal-
thy subjects, the increase of CGT intensity is pro-
portional to the incubation time. CGT values in lym-
phocytes from healthy control subjects and tested
in vitro additionally increase under the influence of
sulfonylurea and insulin.
2. In type 2 diabetes mellitus, therapeutically naive, the
CGT is diminished in comparison to the healthy con-
trol group. This difference is statistically significant.
The reaction of CGT to the addition of sulfonylurea
or insulin is also reduced.
3. A prolonged routine controlled diet and sulfonylu-
rea therapy, lasting 12 weeks, caused a statistically
significant increase in CGT. In type 2 diabetic pa-
tients treated with diet and sulfonylurea, the incre-
ase in CGT reaches the level encountered in control
subjects. This change coexists with a decrease in
GLUT4 expression. Under the influence of diet and
sulfonylurea routine therapy, the elevated GLUT4
expression exhibited before treatment decreased to
the level observed in control subjects.
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